证券之星消息，截至2025年8月14日收盘，港通医疗(301515)报收于23.58元，下跌1.34%，换手率 7.92%，成交量5.05万手，成交额1.19亿元。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 该股主要指标及行业内排名如下： | 指标 | 港通医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 23.58亿元 | 117.92亿元 | 118 123 | | 净资产 | 12.48亿元 | 38.99亿元 | 98 123 | | 净利润 | 157.9万元 | 7941.99万元 | 99 123 | | 市盈率(动) | 373.35 | 64.88 | 95 123 | | 市净率 | 1.91 | 3 ...

Group 1 - The core point of the article highlights the financing activities of Kangtong Medical, which had a financing buy-in amount of 0.15 billion yuan on August 11, ranking 2087 in the market [1] - Over the last three trading days from August 7 to August 11, Kangtong Medical received financing buy-ins of 0.08 billion yuan, 0.17 billion yuan, and 0.15 billion yuan respectively [1] - On the same day, the company had a financing repayment amount of 0.11 billion yuan, resulting in a net buy of 4.1457 million yuan [1] Group 2 - In terms of securities lending, there were no shares sold or net sold on that day, indicating no activity in this area for Kangtong Medical [2]

Group 1 - The core point of the article highlights that Kangtong Medical (301515) has recently registered a new software copyright for the "Medical Gas Alarm System Software V1.0" project, marking a total of 11 new software copyrights registered this year, which is a 57.14% increase compared to the same period last year [1] - In 2024, the company invested 24.2452 million yuan in research and development, which represents a year-on-year decrease of 18.83% [1] - Kangtong Medical has made investments in 12 enterprises and participated in 2,973 bidding projects, indicating active engagement in the market [1] Group 2 - The company holds 31 trademark registrations, 310 patents, and 35 copyright registrations, showcasing a robust intellectual property portfolio [1] - Additionally, Kangtong Medical possesses 106 administrative licenses, further indicating its compliance and operational capabilities within the industry [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Kangtong Medical, which closed at 23.22 yuan with a PE ratio of 438.66, marking a new low in 336 days, and a total market capitalization of 2.322 billion yuan [1][2] - The average PE ratio for the medical device industry is 54.79, with a median of 37.86, positioning Kangtong Medical at 121st in the industry ranking [1][2] - The company experienced a net inflow of 6.5078 million yuan in principal funds on August 7, with a total inflow of 5.2917 million yuan over the past five days [1] Group 2 - Kangtong Medical specializes in the research, design, manufacturing, integration, and operation services of medical gas equipment and clean equipment, with its main products including medical gas equipment and systems [1] - The latest financial report for Q1 2025 shows a revenue of 24.2867 million yuan, a year-on-year decrease of 68.09%, and a net profit of 1.579 million yuan, down 85.25%, with a gross profit margin of 36.15% [1]

Group 1 - The core point of the article highlights that Kangtong Medical (301515) has recently registered a new software copyright for its "Medical Oxygen Machine Control System Software V1.0" project, marking a total of 10 new software copyrights registered this year, which is an increase of 66.67% compared to the same period last year [1] - In terms of research and development, the company invested 24.2452 million yuan in 2024, which represents a year-on-year decrease of 18.83% [1] - Kangtong Medical has made investments in 12 enterprises and participated in 2,965 bidding projects, indicating active engagement in the market [1] Group 2 - The company holds 31 trademark registrations, 309 patent registrations, and 34 copyright registrations, showcasing a strong intellectual property portfolio [1] - Additionally, Kangtong Medical possesses 106 administrative licenses, further indicating its operational capabilities and compliance [1]

Company Overview - The company, Sichuan Portong Medical Equipment Group Co., Ltd., specializes in the research, design, manufacturing, integration, and operation services of medical gas equipment and systems, as well as medical clean equipment and systems [1] - The main products include medical gas equipment and systems, medical clean equipment and systems, medical devices, and other sales and operation services [1] - The company has received multiple accolades, including "National Specialized and Innovative Small Giant Enterprise" and "National High-tech Enterprise" [1] Financial Performance - As of the first quarter of 2025, the company reported a revenue of 24.29 million yuan, representing a year-on-year decrease of 68.09% [1] - The net profit for the same period was 1.58 million yuan, down 85.25% year-on-year, with a sales gross margin of 36.15% [1] Market Position - The company's stock closed at 22.96 yuan, with a rolling price-to-earnings (PE) ratio of 433.75, marking a new low in 334 days [1] - The average PE ratio for the medical device industry is 54.24, with a median of 37.92, placing the company at 121st in industry rankings [1][2] - Only one institution holds shares in the company, with a total holding of 210 shares valued at 0.00 billion yuan [1]

证券代码：301515 证券简称：港通医疗 公告编号：2025-046 四川港通医疗设备集团股份有限公司 关于2024年第二次回购公司股份进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 四川港通医疗设备集团股份有限公司（以下简称"公司"）于 2024 年 11 月 4 日召开第四届董事会第十七次会议和第四届监事会第十七次会议，审议通过 《关于 2024 年第二次回购公司股份方案的议案》，公司拟使用不低于人民币 5,000 万元（含）且不超过人民币 10,000 万元（含）的自有资金和专项回购贷款 资金以集中竞价交易的方式回购公司已发行的人民币普通股（A 股）股票，回购 价格不超过人民币 28.49 元/股（含），回购的股份将用于实施员工持股计划或股 权激励。本次回购股份的实施期限为自公司董事会审议通过本次回购股份方案之 日起不超过 12 个月。具体回购股份的数量以回购期满或回购完毕时公司实际回 购的股份数量为准。 公司于 2024 年 11 月 8 日召开 2024 年第一次临时股东会，审议通过《关于 公司 2024 年前三季度利润分配预案的议案》 ...

Summary of Key Points Core Viewpoint - 港通医疗 has shown a slight increase in shareholder numbers, with a modest rise in average shareholding value despite a small decrease in average shareholding quantity [1] Group 1: Shareholder Statistics - As of July 31, 2025, 港通医疗 had 8,816 shareholders, an increase of 100 from the previous period, representing a growth rate of 1.15% [1] - The average number of shares held per shareholder decreased from 11,500 shares to 11,300 shares [1] - The average market value of shares held per shareholder increased from 245,200 yuan to 249,500 yuan [1] Group 2: Stock Performance - During the observed period, 港通医疗's stock price increased by 4.28% [1] - As of the latest report, 港通医疗's stock price was 22.68 yuan, reflecting a decrease of 0.31% [1] - The company's market capitalization stands at 2.268 billion yuan [1] Group 3: Historical Data Comparison - The changes in shareholder numbers and average holdings over the last five reporting dates are as follows: - July 31, 2025: 8,816 shareholders, 11.3 million shares, 249.5 thousand yuan - July 18, 2025: 8,716 shareholders, 11.5 million shares, 245.2 thousand yuan - July 10, 2025: 9,194 shareholders, 9.1 million shares, 231.7 thousand yuan - June 30, 2025: 8,154 shareholders, 11.2 million shares, 249.3 thousand yuan - June 20, 2025: 7,958 shareholders, 12.6 million shares, 233.7 thousand yuan [1]

Core Viewpoint - As of August 1, 2025, Kangtong Medical (301515) closed at 22.75 yuan, marking a 3.41% increase, with a trading volume of 37,000 hands and a turnover of 83.2752 million yuan [1] Financial Performance - The company reported a main revenue of 24.2867 million yuan for Q1 2025, a year-on-year decline of 68.09% - The net profit attributable to shareholders was 1.579 million yuan, down 85.25% year-on-year - The net profit after deducting non-recurring gains and losses was 1.4143 million yuan, a decrease of 86.46% year-on-year - The debt ratio stood at 36.26%, with financial expenses of -515,200 yuan and a gross profit margin of 36.15% [5] Market Activity - On August 1, 2025, the net inflow of main funds was 1.4782 million yuan, accounting for 1.78% of the total turnover - Retail investors experienced a net outflow of 2.1398 million yuan, representing 2.57% of the total turnover [1][2] - The financing balance on August 1, 2025, was 43.3562 million yuan, with a net repayment of financing amounting to 1.502 million yuan [3] Industry Comparison - Kangtong Medical's total market value is 2.275 billion yuan, compared to the industry average of 11.474 billion yuan, ranking 117th out of 122 in the medical device industry - The company's net assets are 1.248 billion yuan, significantly lower than the industry average of 3.918 billion yuan, ranking 97th out of 122 - The price-to-earnings ratio (P/E) is 360.21, compared to the industry average of 61.54, ranking 94th out of 122 [5]

四川港通医疗设备集团股份有限公司 关于向 2025 年限制性股票激励计划激励对象 证券代码：301515 证券简称：港通医疗 公告编号：2025-045 授予限制性股票的公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1 限制性股票授予日：2025 年 7 月 22 日 限制性股票授予数量：123.00 万股 限制性股票授予价格：10.01 元/股 股权激励方式：第二类限制性股票 1．本次激励计划的激励方式及股票来源 本次激励计划采用的激励工具为限制性股票（第二类限制性股票），涉及的 标的股票来源为公司从二级市场回购的公司 A 股普通股股票或公司向激励对象 定向发行的公司 A 股普通股股票。 2．本次激励计划限制性股票的授予价格 本次激励计划限制性股票的授予价格为 10.13 元/股。（调整前） 3．激励对象的范围 本次激励计划拟激励对象合计 80 人，包括公司公告本次激励计划时在公司 （含控股子公司）任职的高级管理人员、中层管理人员、基层管理人员及核心技 术（业务）骨干。本次激励计划拟激励对象不包括单独或合计持有公司 5%以上 股份的股东 ...